Serenity is developing an immunomodulatory platform called CargoTek. Their initial focus is to improve AAV gene therapy for monogenic diseases like hemophilia A, inherited retinal diseases and neurodegenerative diseases.
In June 2018, Serenity Bioworks closed their Seed round. The amount raised was not disclosed. The round was led by SOSV.
Documentaries, videos and podcasts